| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Department of Pharmacology and Toxicology, College of Pharmacy [S. H. A., A. E. W., O. R. B.] and Department of Pathology, College of Veterinary Medicine [K. W. P., R. L. F.], University of Georgia, Athens, GA 30602; and Department of Preventive Medicine and Community Health [R. C.], University of Texas Medical Branch, Galveston, Texas 77550-2779
Virgin female Sprague-Dawley rats (50 days of age) were administered a single intragastric 10-mg dose of 7,12-dimethylbenz(a)anthracene (DMBA). Twenty-one days later they were placed on diets containing either 20% corn oil (CO), 15% menhaden oil plus 5% corn oil (MO + CO0, 20% CO plus 0.5% w/w of the irreversible ornithine decarboxylase inhibitor, D,L-2-difluoromethylornithine (CO + DFMO), 20% CO plus 0.004% w/w of the cyclooxygenase inhibitor indomethacin (CO + INDO), 20% CO + 0.004% INDO + 0.5% DFMO (CO + INDO + DFMO), or 15% MO + 5% CO + 0.5% DFMO (MO + CO + DFMO). The incidence of DMBA-induced mammary tumors was significantly reduced in rats fed diets containing DFMO but not in rats fed the diet containing indomethacin. Incidences of mammary tumors at 16 weeks post-DMBA were 86% in rats fed the CO diet, 83% in rats ingesting the diet containing CO + INDO, 28% in rats fed CO + DFMO, 32% in rats fed diet containing CO + INDO + DFMO, 59% in rats fed the MO + CO diet, and 24% in rats fed the MO + CO + DFMO diet. The average number of tumors and tumor burden per tumor-bearing rat were reduced and tumor latency was increased in all rats fed diets containing DFMO. Body weight gain, but not food intake, of rats fed the 20% fat + 0.5% DFMO diets was significantly less than in rats fed the 20% fat diets. Prostaglandin E and leukotriene (LTB4) syntheses, ODC activity and mammary tumorigenesis were significantly inhibited by feeding the diet containing menhaden oil or by adding 0.5% DFMO to any of the high fat diets. Feeding a 20% CO diet containing 0.004% INDO significantly reduced prostaglandin synthesis and ODC activity and increased LTB4 synthesis of mammary tumors but did not inhibit mammary tumorigenesis. This study suggests that the 5-lipoxygenase product LTB4 may be involved in mammary tumor production. Whereas a decrease in LTB4 appears to be associated with a decrease in tumorigenesis, an increase (as seen in the indomethacin group) was not associated with any change in the tumorigenic response.
1 Supported in part by grants received from Amideast and the Egyptian Cultural and Education Bureau.
2 To whom requests for reprints should be addressed, at Department of Pharmacology and Toxicology, College of Pharmacy, University of Georgia, Athens, GA 30602.
Received 6/21/88. Revised 10/12/88. Revised 12/13/88. Accepted 12/20/88.
This article has been cited by other articles:
![]() |
P. D. Terry, J. B. Terry, and T. E. Rohan Long-Chain (n-3) Fatty Acid Intake and Risk of Cancers of the Breast and the Prostate: Recent Epidemiological Studies, Biological Mechanisms, and Directions for Future Research J. Nutr., December 1, 2004; 134(12): 3412S - 3420S. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. E. Hardman (n-3) Fatty Acids and Cancer Therapy J. Nutr., December 1, 2004; 134(12): 3427S - 3430S. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. D Terry, T. E Rohan, and A. Wolk Intakes of fish and marine fatty acids and the risks of cancers of the breast and prostate and of other hormone-related cancers: a review of the epidemiologic evidence Am. J. Clinical Nutrition, March 1, 2003; 77(3): 532 - 543. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. E. Hardman Omega-3 Fatty Acids to Augment Cancer Therapy J. Nutr., November 1, 2002; 132(11): 3508S - 3512. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Half, X. M. Tang, K. Gwyn, A. Sahin, K. Wathen, and F. A. Sinicrope Cyclooxygenase-2 Expression in Human Breast Cancers and Adjacent Ductal Carcinoma in Situ Cancer Res., March 1, 2002; 62(6): 1676 - 1681. [Abstract] [Full Text] [PDF] |
||||
![]() |
V. E. Steele, C. A. Holmes, E. T. Hawk, L. Kopelovich, R. A. Lubet, J. A. Crowell, C. C. Sigman, and G. J. Kelloff Lipoxygenase Inhibitors as Potential Cancer Chemopreventives Cancer Epidemiol. Biomarkers Prev., May 1, 1999; 8(5): 467 - 483. [Abstract] [Full Text] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |